Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

Simple item page
dc.contributor.authorCarr, Andrew
dc.contributor.authorRitzhaupt, Armin
dc.contributor.authorZhang, Wei
dc.contributor.authorZajdenverg, Roberto
dc.contributor.authorWorkman, Cassy
dc.contributor.authorGatell, Jose
dc.contributor.authorCahn, Pedro
dc.contributor.authorChaves, Ricardo
dc.date.accessioned2024-03-05T01:56:18Z
dc.date.available2024-03-05T01:56:18Z
dc.date.issued2008-11-12
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractObjectives: Thymidine-based nucleoside analogue reverse transcriptase inhibitors and some protease inhibitors of HIV are associated with lipoatrophy, relative central fat accumulation and insulin resistance. The latter associations have not been well evaluated prospectively in adults commencing antiretroviral therapy. We studied the effects of protease inhibitor-based antiretroviral regimens on body composition, insulin sensitivity and adipocytokine levels. Design: 48-week substudy of a randomized, open-label, three-arm trial. Setting: Hospital and community HIV clinics. Participants: 140 HIV-infected adults naive to antiretroviral therapy. Intervention: Tipranavir/ritonavir [500/200 mg twice a day (TPV/r200)] or [500/100 mg twice a day (TPV/r100)] or lopinavir/ritonavir [400/100 mg twice a day (LPV/r)], each with tenofovir + lamivudine. Main outcome measures: Body composition [dual-energy x-ray absorptiometry for limb fat; L4, abdominal computed tomography for visceral adipose tissue (VAT)]; and fasting metabolic parameters. The primary analysis was change in limb fat mass in each TPV/r group vs. LPV/r. Results: Limb fat increased in all three groups: LPV/r (1.17 kg) versus TPV/r200 (0.83 kg; P = 0.16) and TPV/r100 (0.41 kg; P = 0.07). VAT decreased in all groups: LPV/r (−3 cm2) vs. TPV/r200 (−9 cm2; P = 0.04) and TPV/r100 (−6 cm2; P = 0.40). No significant change in insulin sensitivity was observed, including by oral glucose tolerance testing. The increase in leptin levels was significantly correlated with the increase in limb fat mass (r = 0.67; P < 0.0001). Despite increased limb fat, adiponectin levels increased, but significantly more with TPV/r200 (+6010 ng/ml; P < 0.0001) or TPV/r100 (+4497 ng/ml; P = 0.002) when compared with LPV/r (+1360 ng/ml). Conclusion: Unlike many other antiretroviral regimens, TPV/r or LPV/r with tenofovir-lamivudine increased subcutaneous fat without evidence for increasing visceral fat or insulin resistance over 48 weeks.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/qad.0b013e328315a7a5
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/34
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesAIDS;2008 Nov 12;22(17);2313-21
dc.rightsopenAccesses_ES
dc.subjectAdiponectines_ES
dc.subjectHIVes_ES
dc.subjectInsulin Resistancees_ES
dc.subjectProtease Inhibitorses_ES
dc.titleEffects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adultses_ES
dc.typeArticuloes_ES

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos